Ikan Biotech joins the global concern of antimicrobial resistance and will therefore attend the next congress, in Berlin, on the investigation of new AMR antimicrobials and diagnostics on March 14 and 15.
The objective of this congress is to discuss new strategies in the development of new treatments and antimicrobial diagnostics that can be incorporated into the market and provide new solutions.
The World Health Organization had been warning about for some time, that now there is a global health problem with respect to the effectiveness of existing antibiotics to treat different infections. It is being observed how, little by little, antibiotics are losing their effectiveness because the pathogenic bacteria are becoming resistant, some of which are even resistant to all available antibiotics. As a consequence of the appearance and spreading of the multi-drug resistant pathogenic bacteria, there is a risk to enter an era where we will not be able to treat efficiently common bacterial infections. Several international studies anticipate a number of catastrophic scenarios if a quick solution is not found, one of these scenarios is the death of 10 million people a year by 2050.
What is causing this antimicrobial resistance?
There is a natural factor of evolution of microorganisms normally due to genetic changes, but this natural process has been accelerated by the abuse and misuse of antibiotics, not only in humans, but also in the animal and agri-food sector. To all this, we must add that this microbial resistance can spread between people and animals, including food of animal origin, and person to person.
The question that comes to mind is: What can be done to stop this antimicrobial resistance phenomenon? We must bet on R & D, get investments from both public and private organizations because, as we have said, it is a WORLD health problem. All countries need to develop plans of action in AMR, and we must concentrate on getting a response and coordinated action to reduce the spread and the merit antimicrobial resistance.
Ikan Biotech wants to contribute to stop this major health problem developing new antimicrobial therapies with mechanism of action which minimizes the appearance of resistance and providing models of infection in the Zebra fish with several types of infectious bacteria. We can do pre-clinical assays with the following bacteria:
- Gram positive: Streptococcus equi, Streptococcus iniae, Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, streptococcus uberis
- Gram negative: Acinetobacter baumanii, Enterococcus faecalis, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Pseudomonas aeruginosa, Escherichia coli.